ATE411399T1 - Behandlung der huntington's krankheit mit epa - Google Patents
Behandlung der huntington's krankheit mit epaInfo
- Publication number
- ATE411399T1 ATE411399T1 AT03778516T AT03778516T ATE411399T1 AT E411399 T1 ATE411399 T1 AT E411399T1 AT 03778516 T AT03778516 T AT 03778516T AT 03778516 T AT03778516 T AT 03778516T AT E411399 T1 ATE411399 T1 AT E411399T1
- Authority
- AT
- Austria
- Prior art keywords
- epa
- disease
- treating huntington
- huntington
- treating
- Prior art date
Links
- 208000023105 Huntington disease Diseases 0.000 title abstract 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0228079.0A GB0228079D0 (en) | 2002-12-02 | 2002-12-02 | Huntington's Disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE411399T1 true ATE411399T1 (de) | 2008-10-15 |
Family
ID=9948921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03778516T ATE411399T1 (de) | 2002-12-02 | 2003-11-26 | Behandlung der huntington's krankheit mit epa |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20070148643A1 (de) |
| EP (1) | EP1567667B1 (de) |
| JP (1) | JP2006507833A (de) |
| KR (1) | KR20050086895A (de) |
| CN (1) | CN1717497A (de) |
| AT (1) | ATE411399T1 (de) |
| AU (1) | AU2003285519A1 (de) |
| BR (1) | BR0316969A (de) |
| CA (1) | CA2506727A1 (de) |
| CY (1) | CY1108730T1 (de) |
| DE (1) | DE60324180D1 (de) |
| DK (1) | DK1567667T3 (de) |
| ES (1) | ES2315543T3 (de) |
| GB (1) | GB0228079D0 (de) |
| HR (1) | HRP20050493A2 (de) |
| IS (1) | IS7842A (de) |
| MX (1) | MXPA05005908A (de) |
| MY (1) | MY138759A (de) |
| NO (1) | NO20052955L (de) |
| NZ (1) | NZ539989A (de) |
| PL (1) | PL376101A1 (de) |
| PT (1) | PT1567667E (de) |
| RU (1) | RU2332209C2 (de) |
| SI (1) | SI1567667T1 (de) |
| TW (1) | TWI306120B (de) |
| UA (1) | UA86582C2 (de) |
| WO (1) | WO2004050913A1 (de) |
| ZA (1) | ZA200504003B (de) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007524674A (ja) * | 2004-01-19 | 2007-08-30 | マーテック・バイオサイエンシーズ・コーポレーション | リーリン欠損症または機能障害およびそれに関連する方法 |
| WO2007123391A1 (en) | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
| EP1857548A1 (de) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Mittel und Verfahren zur Induktion von Exon-skipping |
| JP6047270B2 (ja) | 2006-08-11 | 2016-12-21 | バイオマリン テクノロジーズ ベー．フェー． | Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段 |
| JP5706157B2 (ja) | 2007-07-12 | 2015-04-22 | プロセンサ テクノロジーズ ビー．ブイ．Ｐｒｏｓｅｎｓａ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． | 化合物を種々の選択臓器又は組織に標的化するための分子 |
| WO2009008725A2 (en) | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
| DK2203173T3 (en) | 2007-10-26 | 2016-02-29 | Academisch Ziekenhuis Leiden | Materials and methods for prevention of muscle diseases |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| EP2249874A1 (de) | 2008-02-08 | 2010-11-17 | ProSensa Holding BV | Verfahren und mittel zur behandlung von mit dna-repeat-instabilität assoziierten erkrankungen |
| EP2119783A1 (de) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel |
| PT2334295T (pt) | 2008-09-02 | 2017-09-15 | Amarin Pharmaceuticals Ie Ltd | Composição farmacêutica compreendendo ácido eicosapentanoico e ácido nicotínico e métodos de utilização dos mesmos |
| US8293727B2 (en) | 2009-02-10 | 2012-10-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2593836T3 (es) | 2009-04-24 | 2016-12-13 | Biomarin Technologies B.V. | Oligonucleótido que comprende una inosina para tratar la DMD |
| CN107233337A (zh) | 2009-04-29 | 2017-10-10 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
| SI2424356T1 (en) | 2009-04-29 | 2018-01-31 | Armarin Pharmaceuticals Ireland Limited | A stable pharmaceutical composition and procedures for its use |
| WO2010147994A1 (en) | 2009-06-15 | 2010-12-23 | Amarin Pharma, Inc. | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| MX2012003555A (es) | 2009-09-23 | 2012-07-03 | Amarin Corp Plc | Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma. |
| WO2011078672A1 (en) | 2009-12-24 | 2011-06-30 | Prosensa Technologies B.V. | Molecule for treating an inflammatory disorder |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| EP2775837A4 (de) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | Verfahren zur behandlung von hypertriglyceridämie |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| ES2907250T3 (es) | 2012-01-27 | 2022-04-22 | Biomarin Tech Bv | Oligonucleótidos de modulación de ARN con características mejoradas para el tratamiento de la distrofia muscular de Duchenne y de Becker |
| EP3815684B1 (de) | 2012-06-29 | 2024-09-04 | Amarin Pharmaceuticals Ireland Limited | Verfahren zur verringerung des risikos von herz-kreislauf-ereignissen bei einem patienten in einer statintherapie |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| ES2983568T3 (es) | 2018-09-24 | 2024-10-23 | Amarin Pharmaceuticals Ie Ltd | Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto |
| EP4058141A4 (de) | 2019-11-12 | 2023-11-22 | Amarin Pharmaceuticals Ireland Limited | Verfahren zum verringern des risikos von kardiovaskulären ereignissen bei einem probanden mit vorhofflimmern und/oder vorhofflattern |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6A (en) * | 1836-08-10 | Thomas Blanchard | Machine for forming end pieces of plank blocks for ships | |
| US5A (en) * | 1836-08-10 | Thomas Blanchard | Machine for mortising solid wooden shells of ships' tackle-blocks | |
| CA2116280A1 (en) * | 1993-03-05 | 1994-09-06 | Marcy E. Macdonald | Huntingtin dna, protein and uses thereof |
| CA2094169A1 (en) * | 1993-04-16 | 1994-10-17 | Rick E. Preddie | Agents for the prevention and cure of huntington disease in humans: cdna, precursor polypeptide hormone and active hormone reconstructed from the antisense strand of the huntingtondisease gene, "huntingtin" |
| CA2216057A1 (en) * | 1997-09-19 | 1999-03-19 | Ridha Joober | Polymorphic cag repeat-containing gene, diagnosis of psychiatric diseases and therapeutic uses thereof |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| WO2001024781A2 (en) * | 1999-10-07 | 2001-04-12 | Novaneuron Inc. | Gene necessary for striatal function, uses thereof, and compounds for modulating same |
-
2002
- 2002-12-02 GB GBGB0228079.0A patent/GB0228079D0/en not_active Ceased
-
2003
- 2003-11-21 MY MYPI20034492A patent/MY138759A/en unknown
- 2003-11-26 WO PCT/GB2003/005131 patent/WO2004050913A1/en not_active Ceased
- 2003-11-26 CA CA002506727A patent/CA2506727A1/en not_active Abandoned
- 2003-11-26 JP JP2004556479A patent/JP2006507833A/ja active Pending
- 2003-11-26 BR BR0316969-3A patent/BR0316969A/pt not_active IP Right Cessation
- 2003-11-26 HR HR20050493A patent/HRP20050493A2/xx not_active Application Discontinuation
- 2003-11-26 AU AU2003285519A patent/AU2003285519A1/en not_active Abandoned
- 2003-11-26 DK DK03778516T patent/DK1567667T3/da active
- 2003-11-26 EP EP03778516A patent/EP1567667B1/de not_active Expired - Lifetime
- 2003-11-26 SI SI200331472T patent/SI1567667T1/sl unknown
- 2003-11-26 RU RU2005115536/14A patent/RU2332209C2/ru not_active IP Right Cessation
- 2003-11-26 DE DE60324180T patent/DE60324180D1/de not_active Expired - Lifetime
- 2003-11-26 KR KR1020057009802A patent/KR20050086895A/ko not_active Ceased
- 2003-11-26 MX MXPA05005908A patent/MXPA05005908A/es active IP Right Grant
- 2003-11-26 TW TW092133160A patent/TWI306120B/zh active
- 2003-11-26 UA UAA200505201A patent/UA86582C2/ru unknown
- 2003-11-26 ES ES03778516T patent/ES2315543T3/es not_active Expired - Lifetime
- 2003-11-26 PL PL03376101A patent/PL376101A1/xx unknown
- 2003-11-26 NZ NZ539989A patent/NZ539989A/en unknown
- 2003-11-26 CN CNA2003801044204A patent/CN1717497A/zh active Pending
- 2003-11-26 PT PT03778516T patent/PT1567667E/pt unknown
- 2003-11-26 AT AT03778516T patent/ATE411399T1/de not_active IP Right Cessation
- 2003-11-26 US US10/536,927 patent/US20070148643A1/en not_active Abandoned
-
2005
- 2005-05-12 IS IS7842A patent/IS7842A/is unknown
- 2005-05-18 ZA ZA200504003A patent/ZA200504003B/en unknown
- 2005-06-16 NO NO20052955A patent/NO20052955L/no not_active Application Discontinuation
-
2009
- 2009-01-14 CY CY20091100029T patent/CY1108730T1/el unknown
- 2009-04-24 US US12/429,825 patent/US20090270504A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SI1567667T1 (sl) | 2009-04-30 |
| EP1567667B1 (de) | 2008-10-15 |
| US20090270504A1 (en) | 2009-10-29 |
| CN1717497A (zh) | 2006-01-04 |
| CA2506727A1 (en) | 2004-06-17 |
| PL376101A1 (en) | 2005-12-12 |
| NZ539989A (en) | 2006-11-30 |
| US20070148643A1 (en) | 2007-06-28 |
| DK1567667T3 (da) | 2009-01-12 |
| RU2332209C2 (ru) | 2008-08-27 |
| HK1081598A1 (en) | 2006-05-19 |
| WO2004050913A1 (en) | 2004-06-17 |
| ZA200504003B (en) | 2007-01-31 |
| KR20050086895A (ko) | 2005-08-30 |
| HRP20050493A2 (en) | 2005-10-31 |
| JP2006507833A (ja) | 2006-03-09 |
| AU2003285519A1 (en) | 2004-06-23 |
| MY138759A (en) | 2009-07-31 |
| IS7842A (is) | 2005-05-12 |
| MXPA05005908A (es) | 2005-12-12 |
| NO20052955L (no) | 2005-06-16 |
| DE60324180D1 (de) | 2008-11-27 |
| EP1567667A1 (de) | 2005-08-31 |
| RU2005115536A (ru) | 2006-01-27 |
| PT1567667E (pt) | 2008-11-04 |
| BR0316969A (pt) | 2005-10-25 |
| GB0228079D0 (en) | 2003-01-08 |
| TW200418993A (en) | 2004-10-01 |
| TWI306120B (en) | 2009-02-11 |
| UA86582C2 (ru) | 2009-05-12 |
| CY1108730T1 (el) | 2014-04-09 |
| ES2315543T3 (es) | 2009-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE411399T1 (de) | Behandlung der huntington's krankheit mit epa | |
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| DE60320007D1 (de) | Phenethanolamin-derivate zur behandlung von atemwegserkrankungen | |
| ATE462427T1 (de) | Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren | |
| ATE348808T1 (de) | Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten | |
| ATE331527T1 (de) | Verfahren zur behandlung von brustdrüsenerkrankungen | |
| AU8647101A (en) | Compounds having activity as inhibitors of cytochrome p450rai | |
| ATE531813T1 (de) | System zur überwachung einer bakteriellen tumorbehandlung | |
| ATE446285T1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren | |
| CY1111353T1 (el) | Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης | |
| CY1109666T1 (el) | Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας | |
| ATE298246T1 (de) | Aktiviertes protein c zur behandlung von pankreatitis | |
| ATE252383T1 (de) | Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| ATE330596T1 (de) | Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen | |
| DE602004003173D1 (de) | Verwendung von konjugierter Linolsäure zur Behandlung der Erkältung | |
| CY1110156T1 (el) | Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης | |
| ATE516038T1 (de) | Metallcluster-nanoverbindungen zur behandlung von tumorerkrankungen | |
| DE60313208D1 (de) | Phenyl-piperidin-4-yliden-methyl-benzamidderivate zur behandlung von schmerz oder magen-darm-erkrankungen | |
| DE60219495D1 (de) | Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten | |
| DE60310975D1 (de) | Verwendung von epothilone zur behandlung hyperparathyreoidismus | |
| ATE464042T1 (de) | Verwendung von neboglamine zur behandlung von schizophrenie | |
| ATE418977T1 (de) | Verwendung von phenylacetylderivaten zur herstellung eines arzneimittels zur behandlung der von-hippel-lindau-erkrankung | |
| GB0501156D0 (en) | General cure to diseases idea 3 | |
| ATE297745T1 (de) | Chemische modifizierung von harn von säugern | |
| UA70800C2 (ru) | Способ оптимизации лечебного процесса |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1567667 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |